1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

US FDA Using Platform Ideas Outside Of Formal Designations To Speed Cell and Gene Approvals

 
• By Sarah Karlin-Smith

CBER’s Nicole Verdun said the FDA is using the principles of the platform approach in situations that don’t qualify for the agency’s new incentive.

FDA's Office of Therapeutic Products Director Nicole Verdun
CBER Office of Therapeutics Director Nicole Verdun spoke on a 14 May Cencora webinar. • Source: Cencora ThinkLive Cell and Gene Therapy Summit

The US Food and Drug Administration is applying the principles of the platform technology designation to situations that may not technically qualify for the program in order to speed the approval of multiple indications for cell and gene therapies.

Key Takeaways

  • Sponsors may be able to take advantage of the platform technology designation concept without a qualifying product.

The platform technology pathway was created by the 2022 Food and Drug Omnibus Reform Act to streamline development of products...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

Stakeholders Warn Medicare Payment Proposals For Cell, Gene Therapy Could Hamper Access

 
• By Cathy Kelly

CMS proposals would reduce Medicare payments for cell and gene therapy manufacturing and preparation, which will further disincentivize outpatient or community-based treatment, advocates and sponsors said.

US FDA Compounding Advisory Panel Hit Hardest By Recent Purges

 
• By Sarah Karlin-Smith

A Pink Sheet review found 10 FDA advisory panel members recently pulled off committees despite having time left in their appointed terms.

US FDA Upheaval Forces User Fee Talks To Begin Later Than Usual

 
• By Derrick Gingery

The fall start of PDUFA and GDUFA negotiations could impact the agreement review process and other parts of the schedule intended to ensure it reaches Congress on time.

US FDA Leadership Changes Become Reality TV

 
• By Michael McCaughan

Suddenly the leadership changes at the US FDA’s Center for Biologics Evaluation & Research have begun to feel like a soap opera. That is not a recipe for regulatory predictability.

More from Advanced Technologies

More To Be Done In Biopharma If Korea Is To Achieve Govt AI Vision

 
• By Jung Won Shin

Experts discussed challenges and requirements around adoption of AI and big data tools in South Korea's biopharma sector at a recent forum in Seoul, amid a broader push towards an AI-powered economy by the country's new government.

US FDA Upheaval Forces User Fee Talks To Begin Later Than Usual

 
• By Derrick Gingery

The fall start of PDUFA and GDUFA negotiations could impact the agreement review process and other parts of the schedule intended to ensure it reaches Congress on time.

New US FDA AI Councils Will Focus On Internal, External Policy

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.